Schizophrenia Research
Volume 88, Issue 1 , Pages 111-118 , December 2006

The selective effect of antipsychotics on the different dimensions of the experience of psychosis in schizophrenia spectrum disorders

  • Romina Mizrahi

      Affiliations

    • CAMH, Toronto, Ontario, Canada M5T 1R8
    • Department of Psychiatry, Faculty of Medicine, University of Toronto, Canada
    • ,
  • Michael Kiang

      Affiliations

    • Department of Cognitive Science, University of California, San Diego, California, USA
    • ,
  • David C. Mamo

      Affiliations

    • CAMH, Toronto, Ontario, Canada M5T 1R8
    • Department of Psychiatry, Faculty of Medicine, University of Toronto, Canada
    • ,
  • Tamara Arenovich

      Affiliations

    • Clinical Studies Resource Centre, University Health Network, Toronto, Canada
    • ,
  • R. Michael Bagby

      Affiliations

    • CAMH, Toronto, Ontario, Canada M5T 1R8
    • Department of Psychiatry, Faculty of Medicine, University of Toronto, Canada
    • ,
  • Robert B. Zipursky

      Affiliations

    • CAMH, Toronto, Ontario, Canada M5T 1R8
    • Department of Psychiatry, Faculty of Medicine, University of Toronto, Canada
    • ,
  • Shitij Kapur

      Affiliations

    • CAMH, Toronto, Ontario, Canada M5T 1R8
    • Department of Psychiatry, Faculty of Medicine, University of Toronto, Canada
    • Corresponding Author InformationCorresponding author. Centre for Addiction and Mental Health, 33 Russell Street, Toronto, Ontario, Canada M5S 2S1. Tel.: +1 416 979 6890; fax: +1 416 260 4206.

Received 3 February 2006 ,Revised 4 July 2006 ,Accepted 10 July 2006.

References 

  1. Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch. Gen. Psychiatry. 2003;60:1228–1235
  2. Andreasen NC, Arndt S, Alliger R, Miller D, Flaum M. Symptoms of schizophrenia. Methods, meanings, and mechanisms. Arch. Gen. Psychiatry. 1995;52:341–351
  3. APA . Diagnostic and Statistical Manual of Mental Disorders. 4th ed.. Washington, DC: American Psychiatric Association; 1994;
  4. Appelbaum PS, Robbins PC, Roth LH. Dimensional approach to delusions: comparison across types and diagnoses. Am. J. Psychiatry. 1999;156:1938–1943
  5. Brett-Jones J, Garety P, Hemsley D. Measuring delusional experiences: a method and its application. Br. J. Clin. Psychol. 1987;26(Pt 4):257–265
  6. Buchanan RW, Carpenter WT. Domains of psychopathology: an approach to the reduction of heterogeneity in schizophrenia. J. Nerv. Ment. Dis. 1994;182:193–204
  7. Buchanan A, Reed A, Wessely S, Garety P, Taylor P, Grubin D, et al. Acting on delusions. II: the phenomenological correlates of acting on delusions. Br. J. Psychiatry. 1993;163:77–81
  8. Carmines EG, Zeller RA. Reliability and Validity Assessment. Quantitative Applications in the Social Sciences. Sage Publications; 1979;
  9. Chouinard G, Miller R. A rating scale for psychotic symptoms (RSPS): part II: subscale 2: distraction symptoms (catatonia and passivity experiences subscale 3: delusions and semi-structured interview (SSCI-RSPS). Schizophr. Res. 1999;38:123–150
  10. DeVellis RF. In: Scale Development: Theory and Applications. Newbury Park, CA: Sage; 1991;p. 77
  11. Eisen JL, Phillips KA, Baer L, Beer DA, Atala KD, Rasmussen SA. The Brown Assessment of Beliefs Scale: reliability and validity. Am. J. Psychiatry. 1998;155:102–108
  12. Elkes J, Elkes C. Effect of chlorpromazine on behaviour of chronically overactive psychotic patients. Br. Med. J. 1954;2:560–565
  13. Garety PA, Freeman D. Cognitive approaches to delusions: a critical review of theories and evidence. Br. J. Clin. Psychol. 1999;38(Pt 2):113–154
  14. Garety PA, Hemsley DR. Characteristics of delusional experience. Eur. Arch. Psychiatr. Neurol. Sci. 1987;236:294–298
  15. Gur RE, Mozley PD, Resnick SM, Levick S, Erwin R, Saykin AJ, et al. Relations among clinical scales in schizophrenia. Am. J. Psychiatry. 1991;148:472–478
  16. Haddock G, McCarron J, Tarrier N, Faragher EB. Scales to measure dimensions of hallucinations and delusions: the psychotic symptom rating scales (PSYRATS). Psychol. Med. 1999;29:879–889
  17. Harrow MF, Rattenbury F, Stoll F. Schizophrenic delusions: an analysis of their persistence, of related premorbid ideas, and of three major dimensions. In:  Oltmanns TF, M.B.A.  editor. Delusional Beliefs. New York: John Wiley & Sons; 1988;p. 184–211
  18. Harrow M, MacDonald AW, Sands JR, Silverstein ML. Vulnerability to delusions over time in schizophrenia and effective disorders. Schizophr. Bull. 1995;21:95–109
  19. Hole RW, Rush AJ, Beck AT. A cognitive investigation of schizophrenic delusions. Psychiatry. 1979;42:312–319
  20. Johnstone EC, Crow TJ, Frith CD, Carney MW, Price JS. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet. 1978;1:848–851
  21. Jorgensen P. Recovery and insight in schizophrenia. Acta Psychiatr. Scand. 1995;92:436–440
  22. Jorgensen P, Jensen J. What predicts the persistence of delusional beliefs?. Psychopathology. 1994;27:73–78
  23. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2003;27:1081–1090
  24. Kapur S, Arenovich T, Agid O, Zipursky R, Lindborg S, Jones B. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am. J. Psychiatry. 2005;162:939–946
  25. Kay SR, Sevy S. Pyramidical model of schizophrenia. Schizophr. Bull. 1990;16:537–545
  26. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13:261–276
  27. Kendler KS, Glazer WM, Morgenstern H. Dimensions of delusional experience. Am. J. Psychiatry. 1983;140:466–469
  28. Leucht S, Busch R, Hamann J, Kissling W, Kane JM. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol. Psychiatry. 2005;57:1543–1549
  29. Liddle PF. The symptoms of chronic schizophrenia. A re-examination of the positive–negative dichotomy. Br. J. Psychiatry. 1987;151:145–151
  30. Lindenmayer JP, Grochowski S, Hyman RB. Five factor model of schizophrenia: replication across samples. Schizophr. Res. 1995;14:229–234
  31. McDonald RP, Ho MH. Principles and practice in reporting structural equation analyses. Psychol. Methods. 2002;7:64–82
  32. McIntosh AM, Forrester A, Lawrie SM, Byrne M, Harper A, Kestelman JN, et al. A factor model of the functional psychoses and the relationship of factors to clinical variables and brain morphology. Psychol. Med. 2001;31:159–171
  33. Mizrahi R, Bagby RM, Zipursky RB, Kapur S. How antipsychotics work: the patients' perspective. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2005;29:859–864
  34. Oulis PG, Mavreas VG, Mamounas JM, Stefanis CN. Formal clinical characteristics of delusional beliefs. Psychopathology. 1996;29:201–208
  35. Peters ER, Joseph SA, Garety PA. Measurement of delusional ideation in the normal population: introducing the PDI (Peters et al. Delusions Inventory). Schizophr. Bull. 1999;25:553–576
  36. Serretti A, Olgiati P. Dimensions of major psychoses: a confirmatory factor analysis of six competing models. Psychiatry Res. 2004;127:101–109
  37. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry. 1998;59(Suppl 20):22–33(quiz 34-57)
  38. Strauss JS. Hallucinations and delusions as points on continua function. Rating scale evidence. Arch. Gen. Psychiatry. 1969;21:581–586
  39. Wessely S, Buchanan A, Reed A, Cutting J, Everitt B, Garety P, et al. Acting on delusions. I: prevalence. Br. J. Psychiatry. 1993;163:69–76
  40. Woerner MG, Mannuzza S, Kane JM. Anchoring the BPRS: an aid to improved reliability. Psychopharmacol. Bull. 1988;24:112–117

PII: S0920-9964(06)00316-1

doi: 10.1016/j.schres.2006.07.013

Schizophrenia Research
Volume 88, Issue 1 , Pages 111-118 , December 2006

Article Tools

* Image Usage & Resolution